Anteris Technologies GlobalAVR +1.62%23 10-Year ROIIC % is 2,154.36 as of Dec. 2025. GuruFocus rates AVR with a GF Score™ of 23/100. The stock has 7 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Anteris Technologies Global ranks better than 99.43% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Anteris Technologies Global's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 2,154.36%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Anteris Technologies Global's 10-Year ROIIC % or its related term are showing as below:
AVR's 10-Year ROIIC % is ranked better than 99.43% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 2.31
vs AVR: 2154.36
Anteris Technologies Global (NAS:AVR) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Anteris Technologies Global 10-Year ROIIC % Related Terms
Anteris Technologies Global 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVR vs INMD, QDEL, SSII: 10-Year ROIIC % Comparison
For the Medical Devices subindustry, Anteris Technologies Global's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's 10-Year ROIIC % falls into.
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -94.136 (Dec. 2025) - -18.281 (Jun. 2015) )
/
( 8.688 (Dec. 2025) - 12.209 (Jun. 2015) )
=
-75.855
/
-3.521
=
2,154.36%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Anteris Technologies Global (AVR) has a 10-Year ROIIC % of 2,154.36 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #4 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 0.59999999999999%.
Is Anteris Technologies Global's 10-Year ROIIC % too high?
Anteris Technologies Global's current 10-Year ROIIC % is 2,154.36. The Medical Devices & Instruments industry median 10-Year ROIIC % is 2.31. Anteris Technologies Global's value of 2,154.36 is 93162.3% above this industry median. Based on the distribution chart, Anteris Technologies Global ranks #4 out of 699 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's 10-Year ROIIC % compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #4 out of 699 companies for 10-Year ROIIC %. This places Anteris Technologies Global in the top 1% of its industry — outperforming the majority of peers. The industry median 10-Year ROIIC % is 2.31. Anteris Technologies Global's value of 2,154.36 is 93162.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.31, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current 10-Year ROIIC % of 2,154.36 is 93162.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current 10-Year ROIIC % is 2,154.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (AVR) has a current 10-Year ROIIC % of 2,154.36. The current 10-Year ROIIC % is 2,154.36 and 93162.3% above the Medical Devices & Instruments industry median of 2.31. Anteris Technologies Global's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Anteris Technologies Global (AVR), the current 10-Year ROIIC % is 2,154.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
23GF Score
Get the complete analysis for AVR
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVR has been successfully added to your 
